Biogen (BIIB) to present new late-breaking Litifilimab Phase 2 AMETHYST data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology annual meeting

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Breakthrough Therapy Designation by the FDA for CLE; AMETHYST Part A results supported the designation CLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurement when left untreated, and has no targeted treatment option